Galapagos NV Company Profile (NASDAQ:GLPG)

Galapagos NV is a Belgium-based biotechnology company. The Company's activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates. As of December 31, 2011, Galapagos NV was, through its subsidiaries, active in Belgium, France, Switzerland, the Netherlands, the United Kingdom, Germany, the United States and Croatia. In April 2014, it sold BioFocus and Argenta service division operations to Charles River Laboratories International.

2. BTIG Research analysts commented, "Supports Thesis for Minimal Function CF Patients Yesterday, Vertex (VRTX, Not Rated) provided top-line results of the first triplet combination studies for Cystic Fibrosis patients with minimal function mutations, which represents 1/3 of the total patient population. Importantly, the triplet combinations also demonstrated improvements with the F508del homozygous population that exceed the clinical benefit of Orkambi. Overall, this first data for triplet therapies provides positive support for the use of two CFTR correctors within one daily regimen. The results from VRTX’s studies are positive for GLPG’s efforts conceptually, but given GLPG’s limited dataset to date, we continue to think that efforts within CF are a ‘show-me’ story. We maintain our Buy rating and $98 PT.   X-440 and VX-152 Triplet Combinations set a new hurdle rate for clinical efficacy: Although the timespans were relatively short, with 29 days studied with VX-440 and 15 days with VX-152, the +9.5% and +7.3% respective improvements of ppFEV1 are impressive within the F508del homozygous population given the study design had a 4 week run-in period with tezacaftor and ivacaftor. Furthermore, the statistically significant improvements in ppFEV1 in both VX-440 and VX-152 studies within the F508del/Min patient population is unprecedented, underscored by the previous failure of the tezacaftor + ivacaftor combination study." (7/20/2017)

3. According to Zacks Investment Research, "Galapagos NV is a biotechnology company. The Company's operating segment consists of Research and Development and Services. Research and Development segment is engaged in the discovery and development of small molecules. Services segment offers drug discovery products and services. Its products include GLPG0634 for the treatment of rheumatoid arthritis and other inflammatory diseases, GLPG1205/GLPG1690 for treating inflammatory bowel disease, GSK2586184 for the treatment of chronic immuno-inflammatory diseases and GLPG0974, to prevent free fatty acid-induced activation and migration of neutrophils which are in different clinical trial. Galapagos NV is headquartered in Mechelen, Belgium. " (7/14/2017)

Are investors shorting Galapagos NV?

Galapagos NV saw a drop in short interest during the month of September. As of September 15th, there was short interest totalling 403,300 shares, a drop of 27.4% from the August 31st total of 555,345 shares. Based on an average daily trading volume, of 105,234 shares, the days-to-cover ratio is presently 3.8 days.

When did Galapagos NV IPO?

(GLPG) raised $161 million in an initial public offering on Thursday, May 14th 2015. The company issued 3,800,000 shares at $42.43 per share. Morgan Stanley, Credit Suisse and Cowen and Company served as the underwriters for the IPO and Nomura and Bryan, Garnier were co-managers.

Who sold Galapagos NV stock? Who is selling Galapagos NV stock?

Galapagos NV's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Tekla Capital Management LLC, P.A.W. Capital Corp, Employees Retirement System of Texas and Peregrine Capital Management LLC. View Insider Buying and Selling for Galapagos NV.

MarketBeat's community ratings are surveys of what our community members think about Galapagos NV and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.

MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.